Jim Kling

700 total citations
55 papers, 495 citations indexed

About

Jim Kling is a scholar working on Molecular Biology, Public Health, Environmental and Occupational Health and Genetics. According to data from OpenAlex, Jim Kling has authored 55 papers receiving a total of 495 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 10 papers in Public Health, Environmental and Occupational Health and 7 papers in Genetics. Recurrent topics in Jim Kling's work include Biotechnology and Related Fields (8 papers), Science, Research, and Medicine (7 papers) and CRISPR and Genetic Engineering (4 papers). Jim Kling is often cited by papers focused on Biotechnology and Related Fields (8 papers), Science, Research, and Medicine (7 papers) and CRISPR and Genetic Engineering (4 papers). Jim Kling collaborates with scholars based in United States and Sweden. Jim Kling's co-authors include Hepeng Jia, Jun–ei Obata, Deborah Chyun, John Fox, Laura DeFrancesco, Greg McPherson, Victoria Blom and Örjan Ekblom and has published in prestigious journals such as Nature, Science and Nature Biotechnology.

In The Last Decade

Jim Kling

46 papers receiving 461 citations

Peers

Jim Kling
Hai Liao China
Chelsea McLean Netherlands
Joshua D. Levin United States
George S Mack United States
You Wang China
Mark R. Condina Australia
Hai Liao China
Jim Kling
Citations per year, relative to Jim Kling Jim Kling (= 1×) peers Hai Liao

Countries citing papers authored by Jim Kling

Since Specialization
Citations

This map shows the geographic impact of Jim Kling's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jim Kling with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jim Kling more than expected).

Fields of papers citing papers by Jim Kling

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jim Kling. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jim Kling. The network helps show where Jim Kling may publish in the future.

Co-authorship network of co-authors of Jim Kling

This figure shows the co-authorship network connecting the top 25 collaborators of Jim Kling. A scholar is included among the top collaborators of Jim Kling based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jim Kling. Jim Kling is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Kling, Jim. (2021). MODs in need. Lab Animal. 50(4). 79–81. 1 indexed citations
3.
Kling, Jim. (2020). Get a look at Galleria. Lab Animal. 49(3). 65–67. 7 indexed citations
4.
Kling, Jim. (2020). CRISPR gets crunchy. Lab Animal. 50(1). 9–11. 1 indexed citations
5.
Kling, Jim. (2020). The basics of biocontainment. Lab Animal. 49(10). 285–287.
6.
Kling, Jim. (2019). To wild depths for new models. Lab Animal. 48(8). 227–230. 1 indexed citations
7.
Kling, Jim. (2019). Largest Race-Based Survival Advantage to Date Seen in Men Receiving Sipuleucel-T for Prostate Cancer. 1 indexed citations
8.
Kling, Jim. (2018). DIY goes in vivo. Lab Animal. 47(6). 143–146. 1 indexed citations
9.
Kling, Jim. (2014). Sanofi to propel inhalable insulin Afrezza into market. Nature Biotechnology. 32(9). 851–852. 11 indexed citations
10.
Kling, Jim. (2014). Labeling for better or worse. Nature Biotechnology. 32(12). 1180–1183. 8 indexed citations
11.
Kling, Jim. (2012). Beyond counting tumor cells. Nature Biotechnology. 30(7). 578–580. 51 indexed citations
12.
Kling, Jim. (2011). Biotechs follow big pharma lead back into academia. Nature Biotechnology. 29(7). 555–556. 10 indexed citations
13.
Kling, Jim. (2008). Inhaled insulin's last gasp?. Nature Biotechnology. 26(5). 479–480. 39 indexed citations
14.
Kling, Jim & Greg McPherson. (2008). Greener cities: U.S. Forest Service software package helps cities manage their urban treescape. 1 indexed citations
15.
Kling, Jim & Laura DeFrancesco. (2007). The paper trail to commercialization. Nature Biotechnology. 25(11). 1217–1217. 4 indexed citations
16.
Kling, Jim. (2006). Amgen becomes a stronger cancer player. Nature Biotechnology. 24(2). 119–119. 1 indexed citations
17.
Kling, Jim. (2005). Where the future went. EMBO Reports. 6(11). 1012–1014. 3 indexed citations
18.
Kling, Jim. (2001). Research Profiles: Multipurpose nanopore sensors. Analytical Chemistry. 73(11). 306 A–306 A. 1 indexed citations
19.
Kling, Jim. (1997). Lee Hood: still climbing mountains. Current Biology. 7(9). R523–R523. 3 indexed citations
20.
Kling, Jim. (1963). RECORDING RESPONDING IN THE UNDERGRADUATE LABORATORY COURSE. Journal of the Experimental Analysis of Behavior. 6(3). 316–316.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026